<p>Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by disrupted mucosal integrity and immune dysregulation. Emerging evidence increasingly supports postbiotics and paraprobiotics as safer, mechanistically targeted alternatives to conventional therapies such as corticosteroids and biologics. Unlike live probiotics, these non-viable microbial derivatives act through defined immune-metabolic pathways that enhance epithelial barrier function, rebalance gut dysbiosis, and modulate oxidative and inflammatory signalling without infection risk or viability concerns. Preclinical studies demonstrate their capacity to inhibit NF-κB activation, promote regulatory T-cell responses, and restore tight-junction integrity, while early clinical investigations suggest symptom improvement and mucosal healing in subsets of UC patients. Despite these advances, translation remains constrained by limited human trials, lack of standardized formulations, dose–response variability, and regulatory ambiguity. This review critically examines mechanistic, preclinical, and clinical findings on postbiotic and para probiotic interventions in UC, highlighting both their therapeutic promise and the translational gaps that must be bridged for clinical implementation.</p>